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Heritable skin diseases comprise a
group of disorders with highly variable
phenotypic presentations and candidate
genes. Pathogenic mutations in as many
as 500 different genes have been identi-
fied that explain the cutaneous manifes-
tations (Uitto, 2012a). Many of these
diseases are rare, defined in the United
States by o200,000 individuals with
the same diagnosis; the definition of a
rare disease in the European Union is
o5 patients per 10,000 population; the
Japanese definition is fewer than 50,000
patients; no official definition has been
established in China as yet. Although
individually these diseases are rare,
there are close to 7,000 rare diseases,
and thus the total number of individuals
affected by rare diseases in the United
States amounts to B26 million people;
by the same definition, there are as
many as 150 million people in China
affected by rare diseases (Francis
Collins, personal communication, cited
in reference Gaestel, 2012).
Identification of mutated genes in
these diseases has major implications
for appropriate diagnosis and subclassi-
fication with prognostic implications, for
genetic counseling concerning the risk
of transmission, and it has formed the
basis for development of prenatal and
preimplantation genetic diagnosis as
well as presymptomatic testing. Further-
more, identification of specific muta-
tions allows for development of gene
and cell-based therapies, toward allele-
specific treatment, as part of persona-
lized medicine (Uitto et al., 2012; Uitto,
2012b).
Pseudoxanthoma elasticum (PXE), a
prototype of ectopic heritable minerali-
zation disorders, affects clinically the
skin, eyes, and cardiovascular system,
with considerable morbidity and occa-
sional mortality (Uitto et al., 2010;
Li and Uitto, 2013). The major compli-
cations include loss of visual acuity
leading to blindness, and cardiovascular
complications manifesting with nephro-
genic hypertension, intermittent claudi-
cation, and occasional myocardial
infarcts and stroke. Most cases of classic
PXE are caused by mutations in the
ABCC6 gene, which encodes a puta-
tive efflux transporter protein expressed
primarily in the liver and kidneys, and,
at very low level, if at all, in cells in
the affected tissues. Consequently,
based on clinical observations and
development of model systems, such
as Abcc6-/--knockout mice, PXE is
currently considered to be a metabolic
disorder (Uitto et al., 2013). PXE
demonstrates considerable both intra-
and interfamilial heterogeneity, and it
has been suggested that modifier genes,
epigenetic factors, and life-style varia-
bles, including diet, can modify the
severity of the phenotype. Thus, PXE is
a heritable disease at the DNA/environ-
ment interface. There is currently no
effective or specific treatment for the
systemic manifestations of PXE.
The prevalence of PXE is estimated to
beB1:50,000, which implies that there
are as many as 7,000 patients in the
United States and up to 45,000 in
China. Although specific ABCC6 muta-
tions have been disclosed in over 600
PXE families in the United States and
Europe, very little is known of the
mutation profile in Chinese patients
(Uitto et al., 2013). To facilitate
improved diagnosis and management
of patients with PXE, we officially
dedicated the Center of Excellence on
PXE Research and Clinical Care in
China in the Fourth Military Medical
University in Xi’an, in February 2013.
This international collaboration between
the Department of Dermatology and
Cutaneous Biology at Jefferson Medical
College and the Department of
Dermatology in Xijing Hospital will
focus on development of a molecular
diagnostics laboratory for mutation
analysis and characterization of the
mineralization phenotypes in Chinese
patients with PXE (Jin et al., 2015). The
establishment of this Center was
facilitated by PXE International, the
premiere patient advocacy organization
advocating globally on behalf of
patients with PXE (Terry et al., 2007),
and supported by a grant from the
Milstein Medical Asian American
Partnership Foundation. It is expected
that this Center will serve as a focus of
continued collaboration on PXE, and it
will also serve as a model to develop
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collaborative efforts on other heritable
skin diseases between the Chinese
investigators and their colleagues in
the United States and Europe.
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